The FDA has approved a new three-drug combination to treat certain types of an aggressive blood cancer called large B-cell lymphoma (LBCL).

The direct antiglobulin test was positive for anti-C3d specificity, with cold agglutinin titer confirming the diagnosis of CAD.

has made a major breakthrough in treating a common and challenging form of cancer called diffuse large B-cell lymphoma (DLBCL). In a clinical trial known as EPCORE NHL-2, the researchers showed ...

Immunohistochemistry (IHC) is a special test used by pathologists to detect specific molecules on cells. It is widely used in clinical ... FL is the second most common subtype of non-Hodgkin’s ...

Intravascular large ... large B-cell lymphoma (DLBCL) and was first described in 1959 (1), and since then, more than 300 cases have been reported in the literature, mostly case reports and small ...

You’ll find dermatologists who have experience with cutaneous T-cell ... lymphoma called systemic anaplastic large cell lymphoma (sALCL) and some patients with advanced mycosis fungoides. Brentuximab ...

Purpose: To seek novel diagnostic approaches, we improved the workflow of cell-free DNA (cfDNA ... This heatmap is the list of lymphoma-related mutations and the numbers of mutated sites in each eye.